Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

This phase 2, open-label, multicenter study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, in relapsed/refractory CD30(+) non-Hodgkin lymphomas. The primary end point was objective response rate (ORR). Key secondary end points included safety, corr...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Horwitz, Steven M., Advani, Ranjana H., Bartlett, Nancy L., Jacobsen, Eric D., Sharman, Jeff P., O’Connor, Owen A., Siddiqi, Tanya, Kennedy, Dana A., Oki, Yasuhiro
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2014
主題:
Clinical Trials and Observations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425442/
https://ncbi.nlm.nih.gov/pubmed/24652992
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-542142
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍